About HLA class I histocompatibility antigen, alpha chain E
HLA class I histocompatibility antigen, alpha chain E (HLA-E) is a protein
from Homo sapiens identified by UniProt accession
P13747, 358 residues long.
MolForge cross-references it against 0 known binders and
408 disease associations.
Target properties
| Protein name | HLA class I histocompatibility antigen, alpha chain E |
| UniProt accession | P13747 |
| Gene | HLA-E |
| Organism | Homo sapiens |
| Length | 358 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (408)
Diseases linked to this target (Open Targets).
- COVID-19 · score 0.48
- hemoglobin measurement · score 0.26
- thyroid gland adenocarcinoma · score 0.25
- neutrophil-to-lymphocyte ratio · score 0.23
- BMI-adjusted waist-hip ratio · score 0.19
- self reported educational attainment · score 0.18
- mucocutaneous lymph node syndrome · score 0.15
- neuritic plaque measurement · score 0.15
- asthma · score 0.14
- MHC class I polypeptide-related sequence B measurement · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P13747-F1 | alphafold | PREDICTED | 87.00 | — |
Amino-acid sequence (358 residues)
MVDGTLLLLL SEALALTQTW AGSHSLKYFH TSVSRPGRGE PRFISVGYVD DTQFVRFDND AASPRMVPRA PWMEQEGSEY WDRETRSARD TAQIFRVNLR TLRGYYNQSE AGSHTLQWMH GCELGPDGRF LRGYEQFAYD GKDYLTLNED LRSWTAVDTA AQISEQKSND ASEAEHQRAY LEDTCVEWLH KYLEKGKETL LHLEPPKTHV THHPISDHEA TLRCWALGFY PAEITLTWQQ DGEGHTQDTE LVETRPAGDG TFQKWAAVVV PSGEEQRYTC HVQHEGLPEP VTLRWKPASQ PTIPIVGIIA GLVLLGSVVS GAVVAAVIWR KKSSGGKGGS YSKAEWSDSA QGSESHSL
Explore HLA class I histocompatibility antigen, alpha chain E with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets